Market Intelligence, Preclinical Progress, and High-Purity Reagents for Nonsense-Mediated Decay (NMD) and Innate Immune Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DHX34 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DHX34 Full-Length & Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. |
View DHX34 Products |
| Gene Delivery | DHX34 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter. |
View DHX34 Products |
| Benchmark Ab | Anti-DHX34 Recombinant Antibody Research-grade positive control for Western Blot / IP. |
View DHX34 Products |
| Validator | DHX34 siRNA Set For specific knockdown verification, NMD rescue, and viral mimicry induction assays. |
View DHX34 Products |
| Related Target: UPF1 | Core NMD pathway interacting partner; synthetic lethality node. | View UPF1 Products |
| Related Target: SMG1 | Kinase regulator in the NMD surveillance complex. | View SMG1 Products |
| Related Target: RIG-I | DDX58 – Pattern recognition receptor; key viral mimicry pathway partner. | View DDX58 Products |
| Related Target: MDA5 | IFIH1 – Co-regulator of innate immune sensing; synergistic RNA helicase pathway. | View IFIH1 Products |
| Related Target: DHX9 | DEAH-family helicase; critical for selectivity counter-screening. | View DHX9 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase / Helicase Activity Screening | Endotoxin-controlled (<1 EU/µg), sequence-verified full-length and ATPase-domain constructs with intact DEAH-box. |
| Helicase Family Selectivity (DHX9, DHX15, DDX3X cross-reactivity) | Homolog panel proteins (DHX9, DHX15) available with >95% purity, verified by mass spec. |
| Cellular Target Engagement & Permeability | Lentivirus particles and validated siRNA for stable knockdown / overexpression lines. |
| Viral Mimicry Induction (On-target ISG expression) | Validated siRNA sets for RIG-I/MDA5 pathway readouts; stable lines for functional verification. |
| False Positives in PPI Assays | High-purity preparations minimize aggregate interference; Endotoxin controlled (<1 EU/µg). |
| Resistance Mutation Profiling | Custom mutant recombinant proteins (ATP-binding site variants) for mechanism and resistance studies. |
Live DHX34 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
DHX34 (DEAH-box helicase 34) is a multifunctional helicase operating at the intersection of two critical pathways: nonsense-mediated mRNA decay (NMD) and innate immune sensing via the RIG-I/MDA5 axis. In NMD, DHX34 serves as a gatekeeper, regulating mRNA surveillance and enabling synthetic lethality in tumors bearing nonsense mutations. In innate immunity, DHX34 negatively regulates RIG-I/MDA5; its inhibition triggers a “viral mimicry” state, enhancing tumor immunogenicity and sensitizing cold tumors to immune checkpoint blockade.
The current pipeline is predominantly in the preclinical and discovery phases. While no DHX34-targeted therapies have entered clinical trials, the field is rapidly converging on small-molecule ATP-competitive or allosteric inhibitors, as well as PROTAC degraders. Key challenges include achieving >100× selectivity over highly homologous DEAH-box family members (DHX9, DHX15) and demonstrating on-target induction of interferon-stimulated genes (ISGs) without off-toxicity. Near-term catalyst (2026–2027): First IND filing expected as early proof-of-concept emerges in microsatellite-stable (MSS) colorectal and other immunologically “cold” tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Early stage biotechs, academic consortia | Solid tumors (colorectal, gastric, MSS); genetic disease | ATPase / helicase assay (Need high-purity recombinant protein & domain truncations) |
| Targeted Protein Degrader (PROTAC) | Specialized degradation labs, emerging platforms | Refractory cancers (solid, hematologic) | Ternary complex formation & selectivity panel (Need full-length protein with intact surface lysines) |
| RNAi/ASO | Preclinical pharms, research institutions | Immuno-oncology combinations; autoimmune | Knockdown validation & ISG readout (Need validated siRNA and lentivirus) |
Key Mutations & Resistance Profiling
Known natural variants (UniProt) include rs12984558 (VAR_057241), rs8113564 (VAR_057242), and a neurodevelopmental disorder-associated variant of uncertain significance (VAR_083625). These mutations serve as starting points for evaluating drug resistance and target engagement. TarMart offers custom mutant recombinant proteins (e.g., ATP-binding domain substitutions) for pre‑clinical resistance profiling and selectivity counter-screens.